

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more lines of systemic treatment (review of TA677)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Yes, that people from ethnic minorities have fewer donor options and are less likely to have allogeneic stem-cell transplantation. The committee concluded that this was not an equalities issue that could be addressed by the economic evaluation, but it was accounted for in its consideration of the most appropriate willingness-to-pay threshold.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on

people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, in section 3.20

Approved by Associate Director: ...Emily Crowe...

Date: 12/12/2025

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more lines of systemic treatment (review of TA677)

Issue date: December 2025